Why Is Access To Hormone Replacement Therapy In Menopause So Difficult?

During menopause, symptoms such as hot flushes, night sweats, sleep disturbance, vaginal dryness, and cognitive fog can significantly affect quality of life in some women. Hormone replacement therapy is considered one of the most effective options for managing these symptoms, but the type, dose, and duration of treatment should be planned individually.

Recently, the focus of discussion has not only been the treatment itself but also access to treatment. In Turkey, reports published in mid-2025 stated that there were ongoing availability problems particularly with estrogen patches and some hormone medicines used in menopause treatment. For women seeking the right form for symptom control, this has made the issues of access and continuity much more visible.

What Is Hormone Replacement Therapy?

Hormone replacement therapy is a treatment approach aimed at replacing estrogen, and when needed progesterone, that declines with menopause. Clinical guidelines recommend an individualized approach in evaluating and managing menopause symptoms, meaning the same treatment plan is not suitable for everyone.

In people whose uterus has been removed, estrogen-only treatment may be used, while in people who still have a uterus, progesterone should be added to protect the uterine lining. For this reason, treatment choice depends not only on symptoms but also on gynecological history, risk profile, and personal preference.

Why Are Gel And Patch Forms Important?

Hormone replacement therapy is not given only as tablets. Health sources state that estrogen can also be used in the form of tablets, patches, gel, spray, and some local vaginal preparations, and that the most suitable form depends on individual risks and preferences. For this reason, gel and patch forms are not merely alternatives; for many people they may be one of the main treatment options.

Transdermal forms such as patches and gel are especially important because they offer a different use and risk profile compared with oral tablets. NHS sources note that the risk of blood clots may be higher with tablets than with patches, gel, or spray, and that patches and gel may therefore be more suitable in some people. A Turkish Cardiology Association bulletin also notes that transdermal estradiol may stand out in moderate cardiovascular risk and that non-oral treatments are preferred in people with increased venous thromboembolism risk.

What Does The Access Problem In Menopause Treatment Mean?

A treatment existing on paper is not the same thing as being truly and sustainably accessible in daily life. In menopause care, the main issue is whether the form recommended by the physician can be found regularly, whether the person can continue it without interruption, and whether the response can be safely monitored during follow-up visits. If continuity is broken, symptoms may return or the person may turn to unsuitable alternatives on her own.

A 2025 report from Turkey stated that estrogen patches and some hormone medicines had been unavailable for months and that some women unable to access them were left untreated or pushed toward unregistered channels. This shows that in menopause care the real question is not only “is treatment available,” but also “is the right treatment safely and consistently accessible?”

Is The Same Treatment Suitable For Every Menopause Patient?

No. Menopause treatment is planned by evaluating age, time since the last menstrual period, whether the uterus is present, personal and family disease history, clotting risk, cardiovascular risk, breast health history, and the severity of symptoms together. That is why guidelines recommend not a standard prescription, but individualized care.

For some people, tablets may be the most practical option, while for others gel or patches may be more suitable. In some people, only local vaginal estrogen may be enough instead of systemic treatment. So the access debate is not simply about “finding any hormone medicine”; it is about finding the right form for the right person.

In Which People Can Transdermal Treatment Stand Out More?

Transdermal treatments, meaning treatments applied through the skin, may become more important especially in people who do not want oral medication or in whom oral treatment needs to be approached more cautiously because of certain risks. The NHS notes that patches and gel do not increase blood clot risk in the way tablets can, and may therefore be more suitable options for some people.

Similarly, in menopause evaluations where cardiovascular risk is considered more carefully, transdermal estrogen is often discussed. The Turkish Cardiology Association bulletin states that transdermal estradiol may be recommended as first-line in moderate cardiovascular risk and that non-oral treatments are preferred in people at risk of venous thromboembolism. This shows that forms such as gel and patches are not only about comfort; for some people they are a clinical preference.

Why Should Menopause Symptoms Be Taken Seriously?

Menopause symptoms are sometimes underestimated, but for many people they can affect functioning and quality of life. Hot flushes, interrupted sleep, fatigue, difficulty concentrating, mood changes, and vaginal symptoms can disrupt everyday life. This is exactly where the main benefit of HRT appears: reducing symptom burden and improving quality of life.

In addition, menopause management is not only about immediate relief. In suitable patients, treatment may require a broader evaluation in terms of bone health and overall well-being. For this reason, instead of dismissing menopause symptoms as “a natural process to endure,” it is more appropriate to address them through professional evaluation.

What Should Be Considered When Planning Treatment?

Before hormone replacement therapy is started, its benefits and risks should be discussed in detail with the person. Guidelines recommend evaluating not only the severity of symptoms but also the person’s preferences, accompanying diseases, and alternative options. In other words, the right treatment is not only the one that suppresses symptoms, but the one that is safe and sustainable.

For this reason, it is not appropriate to choose a product randomly online or start hormones based on advice from others. Especially issues such as clotting history, cardiovascular risk, the presence of the uterus, irregular bleeding, and breast health should be clarified in medical evaluation. The treatment form should also be selected within this clinical framework.

Conclusion

The issue of access to hormone replacement therapy in menopause is not only about medicine availability; it is also about the quality of women’s healthcare and continuity of treatment. Transdermal forms such as gel and patches are clinically meaningful options for many people, so access to these forms is not only a matter of convenience but also of reaching the appropriate treatment.

The most appropriate approach is to evaluate menopause symptoms individually, plan hormone treatment together with personal risks, and choose the treatment form accordingly. As access problems become more visible, women’s ability to reach safe, regular, and physician-supervised menopause care is emerging as an even more important health issue.

Plan Your Menopause Journey More Consciously With Happ Health

Menopause symptoms and hormone therapy options can vary from person to person. In this process, what matters is evaluating symptoms without minimizing them and safely planning the approach that is suitable for you.

With happ health gynecologists, you can better understand which evaluations may matter during menopause, plan your health follow-up more regularly, and organize the support that fits your needs in a more informed way.